Raymond James analyst Buck Horne downgrades NexPoint Residential (NYSE:NXRT) from Outperform to Market Perform.
Piper Sandler Maintains Overweight on Syros Pharmaceuticals, Lowers Price Target to $20
Piper Sandler analyst Edward Tenthoff maintains Syros Pharmaceuticals (NASDAQ:SYRS) with a Overweight and lowers the price target from $27 to $20.